• Totaligent formed a 50/50 joint venture between Aetherium Medical and Japan-based GloMed Solutions, effective May 22, 2026.
• Venture targets commercialization of advanced biologics and medical devices in Japan, broader APAC region.
• Combines Aetherium’s regulatory strategy, IP, know-how, commercialization platform with GloMed’s APAC distribution network.
• Strategy centers on accelerating market entry via medical tourism channels.
• Management committee includes Edward C. DeFeudis, Ivan Klarich, Don Heath.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Totaligent Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202605280805PRIMZONEFULLFEED9727966) on May 28, 2026, and is solely responsible for the information contained therein.